SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is dominating conversations following reports of record-breaking vehicle deliveries for December and the fourth quarter, fueling strong community speculation about the company achieving its first profitable quarter. The electric vehicle maker's performance, alongside extended government subsidies for new energy vehicles in China, is generating bullish sentiment regarding its growth trajectory and competitive position against rivals. Despite some investor concern about market volatility, many remain focused on NIO's operational advancements.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is actively trending after a competitor's Cushing's syndrome treatment received a regulatory decline, clearing a significant market hurdle for Xeris's approved drug, Recorlev. The community is buzzing about this as a massive tailwind, expecting substantial market share gains that bolster XERS's already strong financial performance and promising pipeline. Analysts are reflecting this positive outlook, highlighting the company's compelling growth trajectory.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending due to its strategic sale of Bressner Technology, which has boosted its cash reserves and sharpened its focus on core AI and edge computing. The community is actively discussing the company's recent stronger-than-expected earnings and raised guidance, alongside high anticipation for a significant military contract for 360 situational awareness systems. Many investors view OSS as an undervalued pure-play in the growing Edge AI and defense sectors, highlighting its tight float and institutional interest.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is drawing significant attention following robust Q3 earnings and strategic moves to bolster its ETF business through acquisitions, alongside its prominent role in a rebounding M&A market. The community is actively discussing the stock's impressive run and strategic AI integration efforts, with many anticipating continued strength, while others debate its high valuation and the potential for a stock split.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending amid intense frustration as the biotech sector's (XBI) extended bullish rally continues to defy expectations, leading to significant pressure on this 3x leveraged bear ETF. The community is sharply divided, with many anticipating an imminent, overdue reversal due to XBI's stretched technicals and high RSI, while others caution against fighting the sector's persistent upward momentum.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending sharply higher following the FDA's acceptance of its sNDA for AXS-05 in Alzheimer's disease agitation with Priority Review, setting a PDUFA target in April 2026. This significant regulatory clarity, coupled with positive updates for AXS-12 in narcolepsy and continued strong Auvelity script growth, is fueling widespread optimism among investors. The community is celebrating substantial long-term gains and actively discussing AXSM's potential to become a major CNS powerhouse, anticipating further analyst upgrades and robust performance as the company advances its diverse pipeline and commercial footprint.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending following mixed interim Phase 2 results for its ARCT-032 cystic fibrosis therapy, which showed signs of mucus plug reduction but limited lung function improvement, leading to significant stock volatility. Community sentiment is divided, with many viewing the sharp decline as an overreaction and highlighting the therapy's biological activity, the strength of their mRNA platform, other pipeline assets, and a high-stakes trade secret lawsuit against AbbVie as key discussion points for future value. Simultaneously, discussions around their influenza vaccine candidates are gaining traction amidst concerns over emerging flu variants.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending as its directors and officers extended their share lock-up until September 2026, signaling strong insider confidence and aligning with promising preliminary Phase 3 trial data showing a significant reduction in breast cancer recurrence. The community is actively discussing a potential short squeeze, fueled by an extremely high cost-to-borrow and limited shares available, while long-term investors anticipate a strategic transaction or significant valuation re-rating for this low-float biotech.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals is trending due to the accumulating global regulatory approvals for EKTERLY, its innovative oral on-demand hereditary angioedema treatment, with Japan being the latest market. The community is actively discussing the drug's strong initial sales performance and its significant market advantage as the first oral option, fueling optimism for its global commercialization. Analysts are reinforcing bullish sentiment, recognizing the company's trajectory towards profitability and its strategic position within the biotech sector, with many anticipating further upside.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is currently trending following key regulatory approvals for its Renergen acquisition and new "Overweight" analyst coverage with a bullish price target. Despite these positive developments, community discussion reflects significant frustration over perceived management missteps, repeated commercial shipment delays, and ongoing dilution concerns. This creates a polarized sentiment, balancing long-term potential in critical isotope markets against short-term execution challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The surge followed fresh technical breakouts, with AEHL and FOXX both reclaiming their 50-day moving averages for the first time in multiple weeks.</li><li>Antelope Enterprise’s rally today builds on the massive 109% jump on Monday, its biggest ever intraday percentage gain.</li><li>FOXX stock has gained consecutively for the past four sessions.</li></ul>&nbsp;&nbsp;Shares of Foxx Development Holdings Inc. (FOXX) and Antelope Enterprise Holdings (AEHL) rallied on Tuesday to rise above their 200-day moving averages (200-DMA).AEHL touched the mark for the first time since October 16, while FOXX last traded at this level on September 18.<figure class="image"><a class="st-link-external" href="https://www.tradingview.com/chart/teA7VKVN/?symbol=NASDAQ%3AAEHL" target="_blank" rel="noopener noreferrer nofollow"><img style="aspect-ratio:1296/864;" src="https://news.stocktwits-cdn.com/AEHL_png_49598bc8cb.webp" alt="AEHL.png" width="1296" height="864"></a><figcaption>AEHL's 50-DMA and 200-DMA Indicators on Nov. 25, 2025 | Source: TradingView</figcaption></figure>The rally comes after fresh technical breakouts, as AEHL touched its 50-day moving average on Monday after a month, while FOXX cleared the mark last Friday for the first time in more than two months.<figure class="image"><a class="st-link-external" href="https://www.tradingview.com/chart/teA7VKVN/?symbol=NASDAQ%3AAEHL" target="_blank" rel="noopener noreferrer nofollow"><img style="aspect-ratio:1300/865;" src="https://news.stocktwits-cdn.com/FOXX_png_cea94ed95b.webp" alt="FOXX.png" width="1300" height="865"></a><figcaption>FOXX's 50-DMA and 200-DMA Indicators on Nov. 25, 2025 | Source: TradingView</figcaption></figure>Antelope Enterprise’s rally builds on the massive 109% jump on Monday, which marked the stock’s biggest ever intraday percentage gain.<h2 class="st-heading-2">AEHL’s Bitcoin Drive</h2>The stock caught investors’ attention in July after the company signed a $50 million securities purchase agreement with Streeterville Capital to buy Bitcoin. AEHL had also mentioned that it would continue exploring broader Web3 and digital finance opportunities. Less than a month later, Antelope partnered with BitGo to purchase Bitcoin and store assets on-chain using multi-signature security.<h2 class="st-heading-2">FOXX’s Q1 Results</h2>Last week, Foxx Development reported quarterly revenues of $20.22 million, down from $23.11 million a year earlier, largely due to weaker mobile phone product sales. However, gross profit improved significantly to $2.74 million from $0.40 million.While operating losses narrowed to $0.89 million from $1.81 million in the prior year, net loss widened slightly to $2.87 million due to higher interest expenses. Despite this, loss per share narrowed to $0.42 from $0.65 a year ago.FOXX stock has gained consecutively for the past four sessions, adding over 240%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>The rally in these stocks has driven retail chatter on Stocktwits. Retail sentiment for <a href="https://stocktwits.com/symbol/AEHL">AEHL stock</a> remained in the ‘extremely bullish’ territory for the past 24 hours, amid ‘extremely high’ message volumes.One user expects the rally to continue till the end of the week.<stembedurl>https://stocktwits.com/KingKong53/message/637396683</stembedurl>Retail sentiment surrounding <a href="https://stocktwits.com/symbol/FOXX">FOXX</a> remained ‘bullish’ for the past 24 hours, accompanied by ‘extremely high’ message volumes. A user expects the stock to rise to $7.<stembedurl>https://stocktwits.com/angelburgosg/message/637405181</stembedurl>&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-cety-stock-double-in-value-today/cL52kXjREgR">Why Did CETY Stock Double In Value Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

AEHL, FOXX Stocks Surpass Their 200-DMA Levels Today

Antelope Enterprise Holdings touched the long-term indicator for the first time since October 16, while Foxx Development last traded at this level on September 18.

Equity

Antelope Enterprise Holdings Ltd. engages in the manufacture and sale of ceramics tiles. Its products operates through the Hengda, the Hengdeli or HDL brand, TOERTO, WULIQIAO, and Pottery Capital of Tang Dynasty brands. It offers porcelain, glazed, glazed porcelain, rustic, and polished glazed tiles. The company was founded by Jia Dong Huan on September 30, 1993 and is headquartered in Chengdu, China.

AEHL
Antelope Enterprise Holdings Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest AEHL News

AEHLAntelope Enterprise Holdings Ltd